Frontiers in Cardiovascular Medicine

JUNE 6, 2024

Cardio-oncology is a new field of interest in cardiology focusing on the detection and treatment of cardiovascular diseases, such as arrhythmias, myocarditis, and heart failure, as side-effects of chemotherapy and radiotherapy. The association between chemotherapeutic agents and arrhythmias has previously been established.

Tachycardia 40

Tachycardia Cancer Cardio Oncology Arrhythmia 40

Journal of Clinical Investigation - Cardiology

JANUARY 2, 2024

Cardiovascular diseases are the most common cause of worldwide morbidity and mortality, highlighting the necessity for advanced therapeutic strategies. Here, we extended this therapeutic concept toward potential clinical translation.

Cardiac Function 40

Cardiac Function Ischemia Exercise Cardiovascular Disease 40

Journal of the American Heart Association

NOVEMBER 23, 2023

BackgroundPatients with nonalcoholic fatty liver disease are at increased risk to develop atherosclerotic cardiovascular diseases. Vasomotor activities of aortic rings were altered byGpbar1andFxrgene ablation. Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023.

Aortic 40

Aortic Aneurysm Plaque Cholesterol 40

DAIC

FEBRUARY 14, 2025

In particular, the study showed superiority in the percentage of patients that achieved freedom from atrial fibrillation (AF) with or without anti-arrhythmic drugs at 12 months after a tailored cardiac ablation guided by AI in combination with PVI when compared to PVI alone.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Technology Pulmonary 52

DAIC

DECEMBER 14, 2023

Launching the first FDA -approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency 1. In my clinical experience with the catheter, it was designed for AF ablation procedures.

Atrial Fibrillation 105

Atrial Fibrillation Ablation Technology Heart Failure 105

DAIC

JUNE 25, 2024

HHNM will use the Allia IGS Pulse system in its cardiac electrophysiology (EP) lab to plan, guide and monitor the outcomes of electrophysiological procedures, such as cardiac ablations, cardiac catherizations, transcatheter aortic valve replacements, balloon and coronary angioplasties and more. It’s an honor to have the U.S.’s

Electrophysiology 105

Electrophysiology Hospital Aortic valve Heart Disease 105

Heart BMJ

NOVEMBER 27, 2023

Sleep-disordered breathing (SDB) is common in individuals with established cardiovascular disease (CVD), particularly those with heart failure (HF). In patients with AF and OSA treated with AF ablation, CPAP use was associated with a reduced risk of recurrence of AF.

Cardiovascular Disease 40

Cardiovascular Disease Blood Pressure Atrial Fibrillation Heart Failure 40

DAIC

FEBRUARY 2, 2024

Cardiovascular disease is the leading cause of death globally - affecting millions of individuals and placing a significant burden on healthcare systems today. [1] million people died from cardiovascular diseases in 2019. million people in the United States by 2050 and 17.9 million in Europe by 2060. [2]

Electrophysiology 101

Electrophysiology Innovation AFIB Atrial Fibrillation 101

DAIC

JUNE 19, 2024

While the spotlight in 2023 shone on developments around Generative Artificial Intelligence (AI), away from the limelight a quiet revolution in AI was taking place, which promises to transform the way we diagnose, manage, and treat cardiovascular diseases, the world’s leading cause of death.

AFIB 105

AFIB Reimbursement Research Atrial Fibrillation 105

Cardiometabolic Health Congress

DECEMBER 7, 2023

Furthermore, it includes the latest recommendations which specifically address AF and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, AF catheter or surgical ablation, and risk factor modification and AF prevention. As such, the Class of Recommendation for catheter ablation has been upgraded.

Atrial Fibrillation 111

Atrial Fibrillation Risk Factors Ablation Stroke 111

Cardiometabolic Health Congress

DECEMBER 5, 2024

The American Heart Association (AHA) Congress 2024 , held from November 1618, marked a pivotal moment in cardiovascular and metabolic health. As the AHA celebrates its 100th year, the conference reflected on a century of innovation while exploring the future of cardiovascular disease prevention and management. View the study.

CME 52

CME Obesity Innovation Cardiovascular Disease 52

Dr. S. Venkatesan MD

JANUARY 1, 2025

Top 10 Clinical Trials Preventive PCI on Stenosis With Functionally Insignificant Vulnerable Plaque PREVENT (ACC.24) 24) Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With HF FINEARTS-HF (ESC Congress 2024 and AHA 2024) Randomized Evaluation of Decreased Usage of Beta-Blockers After AMI REDUCE-AMI (ACC.24)

Cardiogenic Shock 59

Cardiogenic Shock Plaque Academic Bicuspid/Mitral 59